The positive effects of secreted WISP2 on mesenchymal tissue hyperplasia and growth, increased circulating levels of adiponectin and PAHSAs and improved insulin sensitivity make WISP2 a novel and attractive target to prevent obesity-related metabolic complications including insulin resistance and Type 2 diabetes. This evidence concerns the gene ADIPOQ and obesity disorder.